Placed on the Union Calendar, Calendar No. 304.
The bill amends the Federal Food, Drug, and Cosmetic Act and related statutes to strengthen pediatric cancer drug study requirements, change PREA enforcement and due-diligence rules, extend rare pediatric disease priority review vouchers, narrow orphan-drug exclusivity, fund pediatric study programs, add Organ Procurement and Transplantation Network authorities and temporary registration fees, create an FDA Abraham Accords Office for international regulatory cooperation, increase transparency for generic drug inactive-ingredient determinations, and raise the Medicare Improvement Fund amount.
Left praises pediatric protections; right worries about FDA expansion and costs
Many provisions are child-health focused and technical; mixed industry concerns but achievable bipartisan support in the House.
The bill amends the Federal Food, Drug, and Cosmetic Act and related statutes to strengthen pediatric cancer drug study requirements, change PREA enforcement and due-diligence rules, extend rare pediatric disease priority review vouchers, narrow orphan-drug exclusivity, fund pediatric study programs, add Organ Procurement and Transplantation Network authorities and temporary registration fees, create an FDA Abraham Accords Office for international regulatory cooperation, increase transparency for generic drug inactive-ingredient determinations, and raise the Medicare Improvement Fund amount.
Substantive, broadly technical health reforms increase appeal but fiscal effects and pharma incentives create meaningful opposition and Senate friction.
How solid the drafting looks.
Left praises pediatric protections; right worries about FDA expansion and costs
These are examples from the analysis, not a ranked list of the most-affected groups.
Left praises pediatric protections; right worries about FDA expansion and costs
Generally favorable: advances pediatric drug testing, increases transparency, and supports organ transplant system improvements.
Concerned about implementation details, potential pharma gaming of priority vouchers, and any procedural delays that reduce pediatric access.
Cautiously supportive: supports more pediatric data, transparency, and transplant system reform while emphasizing oversight, clear guidance, and cost-accountability.
Wants measured implementation and evidence from mandated GAO/HHS reports.
Skeptical: supports pediatric focus but concerned about expanding FDA authority, new foreign office, added fees, and higher Medicare fund.
Worries about regulatory burdens and costs to industry and providers.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive, broadly technical health reforms increase appeal but fiscal effects and pharma incentives create meaningful opposition and Senate friction.
The bill has not accumulated any surfaced votes yet.
Left praises pediatric protections; right worries about FDA expansion and costs
Substantive, broadly technical health reforms increase appeal but fiscal effects and pharma incentives create meaningful opposition and Sen…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Mikaela Naylon Give Kids a Chance Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.